Heterocyclic Compounds and Uses Thereof
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
1 .- 53 . (canceled)
54 . A method of providing therapeutic benefit in a subject having a cancer selected from lung cancer and gastric cancer by inhibiting phosphatidyl inositol-3 kinases comprising administering to the subject a therapeutically effective amount of a compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein
W 1 is CR 3 ;
W 2 is CR 4 ;
W 3 is N;
W 4 is N;
W 5 is CR 7 ;
W 6 is CR 8 ;
R 1 and R 2 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, or carbonate;
R 3 is amido of formula —C(O)N(R) 2 , or —NHC(O)R, wherein R is hydrogen, alkyl, cylcloalkyl, aryl, heteroaryl, or heteroalicyclic; or wherein said (R) 2 groups taken together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, or 7-membered ring; and
R 4 , R 7 and R 8 are each hydrogen.
55 . The method of claim 54 , wherein R 1 is hydrogen and R 2 is amino.
56 . The method of claim 55 , wherein R 2 is NH 2 .
57 . The method of claim 54 , wherein R 3 is amido of formula —C(O)N(R) 2 wherein said (R) 2 groups taken together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, or 7-membered ring.
58 . The method claim 57 , wherein R 1 is hydrogen and R 2 is amino.
59 . The method claim 58 , wherein R 2 is NH 2 .
60 . The method of claim 59 , wherein R 3 is amido of formula —C(O)N(R) 2 wherein said (R) 2 groups taken together with the nitrogen to which they are attached form an optionally substituted 6-membered ring.
61 . The method of claim 54 , wherein the compound or pharmaceutically acceptable salt is
62 . The method of claim 54 , wherein the cancer is lung cancer.
63 . The method of claim 62 , wherein the lung cancer is non-small cell lung cancer.
64 . The method of claim 62 , wherein the lung cancer is small cell lung cancer.
65 . The method of claim 54 , wherein the cancer is gastric cancer.